 CHARLESTON, S.C., Feb. 16, 2021 GLOBE NEWSWIRE -- Aeterna Zentaris Inc. NASDAQ: AEZS TSX: AEZS Aeterna or the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an underwriting agreement with H.C. Wainwright Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 6,896,552 common shares of Aeterna, at a price to the public of 1.45 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions. 